Protocol for therapeutic use of Posaconazolo out of clinical trials in patients with invasive resistant micosis and/or in tolerant patients. - ND

Phase 1

• Conditions: patients with invasive resistant micosis and/or tolerant patients; MedDRA version: 6.1Level: HLTClassification code 10003486

• Registration Number: EUCTR2006-004968-32-IT
• Lead Sponsor: OSPEDALE S. RAFFAELE

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2007-01-10
• Last Update Posted: 26 October 2021

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

-aspergillosis-fusariosis-cromoblastomicosis-coccidiomicosis
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

-pregnancy and breastfeeding;-hypersensibility to azolic anti micotics; -subjects in treatment with vinca or antracicline 24 hours before posaconazolo treatment or subject requiring vinca or antracicline therapy for 30 days or more

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified